Related references
Note: Only part of the references are listed.Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial
J. P. Durand et al.
ANNALS OF ONCOLOGY (2012)
Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity
Paulo M. Hoff et al.
CLINICAL COLORECTAL CANCER (2012)
Oxaliplatin: a review of approved uses
Alexander Stein et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer
Olivier Mir et al.
LUNG CANCER (2012)
Management of advanced gastric cancer
Timothy J. Price et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2012)
Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity
Michele Basso et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis
Junshik Hong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
The Many Faces of Glutathione Transferase Pi
O. Vasieva
CURRENT MOLECULAR MEDICINE (2011)
Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes
M. Inada et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics
Guido Cavaletti et al.
LANCET ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Oxaliplatin-Induced Neuropathy in Colorectal Cancer
Andrew Weickhardt et al.
JOURNAL OF ONCOLOGY (2011)
Associations between glutathione S-transferase π Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy
Masashi Kanai et al.
CANCER EPIDEMIOLOGY (2010)
Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma
Yen-Chung Chen et al.
CANCER SCIENCE (2010)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy?
A. G. Antonacopoulou et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Glutathione S-transferases: an overview in cancer research
Giuliano Di Pietro et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
Howard L. McLeod et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05
Valerie Boige et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer
Qing-Fang Li et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2010)
Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity
O. Mir et al.
ANNALS OF ONCOLOGY (2009)
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients
Dina M. Kweekel et al.
EUROPEAN JOURNAL OF CANCER (2009)
Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
Eray Goekkurt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Liability of the Voltage-Gated Sodium Channel Gene SCN2A R19K Polymorphism to Oxaliplatin-Induced Peripheral Neuropathy
Andreas A. Argyriou et al.
ONCOLOGY (2009)
Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy
L. Pare et al.
BRITISH JOURNAL OF CANCER (2008)
Differential effects of glutathione S-transferase pi (GSTP1) haplotypes on cell proliferation and apoptosis
Sarah L. Holley et al.
CARCINOGENESIS (2007)
Predictive factors of oxaliplatin neurotoxicity: The involvement of the oxalate outcome pathway
Laurence Gamelin et al.
CLINICAL CANCER RESEARCH (2007)
Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy
Annamaria Ruzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy
Thierry Lecomte et al.
CLINICAL CANCER RESEARCH (2006)
Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese
SL Zhong et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
Glutathione S-transferase polymorphisms:: cancer incidence and therapy
CC McIlwain et al.
ONCOGENE (2006)
Heterogeneity testing in meta-analysis of genome searches
E Zintzaras et al.
GENETIC EPIDEMIOLOGY (2005)
The role of glutathione-S-transferase in anti-cancer drug resistance
DM Townsend et al.
ONCOGENE (2003)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli
TM Ishimoto et al.
PHARMACOGENETICS (2002)
Share Paper
